Longeveron LGVN 深 滬
已收盤 08-07 16:00:00 美东时间
0.766
-0.007
-0.97%
華盛通- 最 高0.80
- 今 開0.777
- 成交量 41.67万股
- 最 低 0.7501
- 昨 收 0.7735
- 總市值 2420.40万
- 52周最高 1.23
- 市盈率 靜 --
- 換手率 1.32%
- 52周最低 0.475
- 委 比 -17.16%
- 總股本 3159.80万
- 歷史最高 450.00
- 量 比 0.96
- 振 幅 6.45%
- 歷史最低 0.475
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Longeveron Restores Nasdaq Compliance with New Audit Committee
Longeveron ( ($LGVN) ) just unveiled an announcement. In March 2026, Longeveron...
07-30 04:42
Longeveron Alzheimer’s Therapy Shows Brain Inflammation Benefits, Presents New Alzheimer’s Stem Cell Therapy Data
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestroce...
07-13 19:17
Longeveron grants special equity awards to Executive Chairman
Longeveron ( ($LGVN) ) has shared an announcement. On July 6, 2026, Longeveron,...
07-09 04:31
Longeveron strengthens financial leadership with new CFO appointment
Longeveron ( ($LGVN) ) has issued an update. Longeveron Inc., a clinical-stage ...
07-07 05:27
Longeveron Names Marie Washburn as Chief Financial Officer Effective On July 13; Lisa Locklear To Step Down As CFO
Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company’s executive leadership team in the role of Senior V...
07-07 04:08
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. appoints Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026. With over 20 years of leadership experience in the pharmaceutical and biotech sectors, Washburn previously served as Vice President and Corporate Controller at the company. Her appointment comes as Longeveron anticipates top-line results from its Phase 2b clinical trial for laromestrocel in treating Hypoplastic Left Heart Syndrom...
07-06 20:05
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
Longeveron Inc. announced that additional analysis from its Phase 2a clinical trial of laromestrocel for mild Alzheimer’s disease has been accepted for a poster presentation at the 2026 Alzheimer’s Association International Conference in London. The presentation will occur on July 13, 2026, during the In-Person Posters session. Results from the CLEAR MIND trial were previously published in *Nature Medicine* in March 2025, supporting laromestrocel...
06-18 13:20
Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines Agency
According to the EMA, SME Designation has allowed for improved success rate for organizations seeking regulatory approvals:the success rate for SME marketing authorization applications for human medicines more than
06-09 21:21
Longeveron CFO Lisa Locklear Plans To Step Down, Effective July 10
https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026065788/ea0293758-8k_longeveron.htm
06-06 04:04
Longeveron to Present at BIO International Convention 2026
Longeveron Inc. will participate in the BIO International Convention 2026 to present its stem cell therapy laromestrocel, focusing on potential partnerships for Hypoplastic Left Heart Syndrome, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy, and Aging-related Frailty. The company aims to leverage strategic collaborations to accelerate development and commercialization, with laromestrocel showing positive results across multiple clinical tr...
06-04 13:15
